SMi’s 3rd annual conference
Immunogenicity
13th and 14th June 2016, Holiday In Kensington Forum, London, UK.
Immunogenicity of an antigen is frequently encountered in the context of vaccine development, an area of intense interest currently due to the emergence or re-emergence of infectious pathogens with the potential for worldwide spread. With the global vaccine market expected to reach $84.44 billion by 2022, now is the time engage with industry experts to addresses the real challenges with immunogenicity including assay assessment, the role of aggregation, the introduction of nanobodies and many more!
For further information or to register please visit the event website www.immuno.co.uk or contact Matthew Apps on +44 (0) 207 827 6093 or mapps@smi-online.co.uk
Immunogenicity overview of therapeutic biologicsCreative-Biolabs
The sildes is created by Creative Biolabs. What is immunogenicity? Background of immunogenicity, importance of immunogencity in drug discovery are described in the presentation.
This 3-day event is the meeting place for international and domestic scientists to share case studies and project updates, showcase new techniques and form collaborations that pave the way towards the future of China’s biopharmaceutical industry.
This presentation explains about the Immunoassay ,radio immuno assay, definition, types, Principle , procedure, steps involved ,advantages ,disadvantages ,Application, RIA in insulin. RIA in Digitalis drug ligand etc....
Therapeutic Vaccines for Alzheimer’s — Are We Close Enough?Aranca
Could a vaccine for Alzheimer's be a reality any sooner? Find more on Alzheimer Therapy Market Challenges from Aranca's Technology Intelligence & IP Research Experts.
Immunogenicity overview of therapeutic biologicsCreative-Biolabs
The sildes is created by Creative Biolabs. What is immunogenicity? Background of immunogenicity, importance of immunogencity in drug discovery are described in the presentation.
This 3-day event is the meeting place for international and domestic scientists to share case studies and project updates, showcase new techniques and form collaborations that pave the way towards the future of China’s biopharmaceutical industry.
This presentation explains about the Immunoassay ,radio immuno assay, definition, types, Principle , procedure, steps involved ,advantages ,disadvantages ,Application, RIA in insulin. RIA in Digitalis drug ligand etc....
Therapeutic Vaccines for Alzheimer’s — Are We Close Enough?Aranca
Could a vaccine for Alzheimer's be a reality any sooner? Find more on Alzheimer Therapy Market Challenges from Aranca's Technology Intelligence & IP Research Experts.
This presentation explains about the principle and procedure involved in elisa method of immunoassay, development o f elisa , application advantages and disadvantages of elisa
The basic knowledge of Antibody-drug conjugates (ADC) - Creative BiolabsCreative-Biolabs
In this powerpoint, Creative Biolabs will describe basic knowledge of Antibody-Drug Conjugates (ADC), which includes in definition and mechanism of ADC, and its features and future development direction. We hope this video can help you understand what is ADC and what its application. If you have any question, welcome to cantact us at info@creative-biolabs.com.
PEGS Boston the essential protein engineering summitNicole Proulx
With record-breaking attendance in 2015, PEGS Boston attracts an international delegation of nearly 2,000 participants including conference delegates, speakers, exhibitors, sponsors and guests representing over 30 countries.
Participants value the in-depth short courses, access to 22 conferences, and wide-ranging presentations delivering new unpublished data, case studies, innovation and insight.
The vast exhibit hall will be packed with 125 exhibiting companies and more than 200 research posters on display providing valuable viewing of innovative new technologies, as well as abundant networking with biopharma researchers and industry representatives.
Abstract:
Cell and gene therapies, well recognized as the drug revolution for this decade, are booming in Asian countries. Several cell and gene therapeutic products launched successfully in Europe and the US. The commercialization of these therapies is a hot topic, while ensuring product safety, especially quality for the new modalities, raises challenges within the industry. As a globally leading biosafety testing provider, Merck is committed to optimizing and advancing innovation and development of biosafety testing. As your reliable partner in CMC consideration, our comprehensive solutions for cell and gene therapy biosafety testing enable regulatory compliance. This presentation will cover rationale and methodologies for cell and gene therapy product testing from Merck’s BioReliance® testing portfolio, as well as provide an overview of our testing capabilities and services.
Assignment on General principles of ImmunoassayDeepak Kumar
Assignment on General principles of immunoassay: theoretical basis and optimization of immunoassay, heterogeneous and homogenous immunoassay systems. Immunoassay methods evaluation; protocol outline, objectives and preparation. Immunoassay for digoxin and insulin
This ppt file represents a simple overview on what is antibody validation & how to validate an antibody before performing any research.
Used references are also included.
Does your cell line have a secret? Avoid surprises with characterizationMerck Life Sciences
Watch the recording of this webinar here: https://bit.ly/2Y05bV4
The first step to avoiding an unpleasant and costly contamination event is characterization of your cell banks.
Regardless of the biotech product, careful characterization of the cell banks used in its production is the first step in mitigating the risk of a contamination event. In fact, cell line characterization is an important component of the overall viral safety strategy for the product. We will describe the testing necessary to ensure cell banks are free from infectious and other adverse agents and that meets current regulatory expectations. Different levels of testing are performed for master, working, and end of production cell banks, and the differences in testing for each of these types of banks will be discussed.
In this webinar, you will learn:
• The types of tests that are needed to fully characterize your cell banks
• The best tests to use for your particular cell line
• Reasons why a viral contaminant may be missed
Improving Immunohistochemistry Standardization in your Laboratory: Renewable ...Candy Smellie
What is the impact of assay failure in your laboratory and how do you monitor for it?
To develop genetically defined IHC Reference Standards with consistent protein expression levels for analytic validation and quantitative assessment of immunohistochemistry assays.
Platform Technologies to Accelerate Novel Vaccine Development and ManufacturingMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3jmLYHu
State-of-the-art vaccine technologies are transforming vaccine development, and solutions for fast and reliable production are needed.
The vaccine industry has undergone a revolution in technology resulting in a variety of novel therapeutic platforms that accelerate development and significantly reduce the duration for process optimization and scale-up. However, challenges in maintaining efficacy and improving process robustness remain. In this presentation, we present a comparison of these novel technologies, discuss key considerations for manufacturing and share selected case studies for platforms such as virus-like-particles, viral vectors, plasmid DNA, and mRNA platform.
In this webinar, you will learn:
• Benefits of platform technologies in vaccine development
• Key considerations when deciding between platforms
• Vaccine pipeline analysis and selected case studies
Presented by:
David Loong, Ph.D, Senior Consultant, Novel Modalities Asia Pacific, Bioprocessing Strategy
Josephine Cheng, Senior Consultant, Core Modalities Asia Pacific, Bioprocessing Strategy
Creative Biolabs is a leading service provider that focuses on antibody engineering for research, diagnostic and therapeutic use. Our service portfolio includes antibody affinity maturation, antibody stability improvement, chimeric antigen receptor (CAR) construction, scFv/Fab construction and other antibody specialization and modification services.
Antibody screening is more helpful in identifying the
highly productive cells and is more significant in the
form of laboratory techniques. Complete solution on screening
of antibodies can be effectively offered only
by such kinds of reputed medical institutions.
For more details please visit
http://www.axiomxinc.com/
This presentation explains about the principle and procedure involved in elisa method of immunoassay, development o f elisa , application advantages and disadvantages of elisa
The basic knowledge of Antibody-drug conjugates (ADC) - Creative BiolabsCreative-Biolabs
In this powerpoint, Creative Biolabs will describe basic knowledge of Antibody-Drug Conjugates (ADC), which includes in definition and mechanism of ADC, and its features and future development direction. We hope this video can help you understand what is ADC and what its application. If you have any question, welcome to cantact us at info@creative-biolabs.com.
PEGS Boston the essential protein engineering summitNicole Proulx
With record-breaking attendance in 2015, PEGS Boston attracts an international delegation of nearly 2,000 participants including conference delegates, speakers, exhibitors, sponsors and guests representing over 30 countries.
Participants value the in-depth short courses, access to 22 conferences, and wide-ranging presentations delivering new unpublished data, case studies, innovation and insight.
The vast exhibit hall will be packed with 125 exhibiting companies and more than 200 research posters on display providing valuable viewing of innovative new technologies, as well as abundant networking with biopharma researchers and industry representatives.
Abstract:
Cell and gene therapies, well recognized as the drug revolution for this decade, are booming in Asian countries. Several cell and gene therapeutic products launched successfully in Europe and the US. The commercialization of these therapies is a hot topic, while ensuring product safety, especially quality for the new modalities, raises challenges within the industry. As a globally leading biosafety testing provider, Merck is committed to optimizing and advancing innovation and development of biosafety testing. As your reliable partner in CMC consideration, our comprehensive solutions for cell and gene therapy biosafety testing enable regulatory compliance. This presentation will cover rationale and methodologies for cell and gene therapy product testing from Merck’s BioReliance® testing portfolio, as well as provide an overview of our testing capabilities and services.
Assignment on General principles of ImmunoassayDeepak Kumar
Assignment on General principles of immunoassay: theoretical basis and optimization of immunoassay, heterogeneous and homogenous immunoassay systems. Immunoassay methods evaluation; protocol outline, objectives and preparation. Immunoassay for digoxin and insulin
This ppt file represents a simple overview on what is antibody validation & how to validate an antibody before performing any research.
Used references are also included.
Does your cell line have a secret? Avoid surprises with characterizationMerck Life Sciences
Watch the recording of this webinar here: https://bit.ly/2Y05bV4
The first step to avoiding an unpleasant and costly contamination event is characterization of your cell banks.
Regardless of the biotech product, careful characterization of the cell banks used in its production is the first step in mitigating the risk of a contamination event. In fact, cell line characterization is an important component of the overall viral safety strategy for the product. We will describe the testing necessary to ensure cell banks are free from infectious and other adverse agents and that meets current regulatory expectations. Different levels of testing are performed for master, working, and end of production cell banks, and the differences in testing for each of these types of banks will be discussed.
In this webinar, you will learn:
• The types of tests that are needed to fully characterize your cell banks
• The best tests to use for your particular cell line
• Reasons why a viral contaminant may be missed
Improving Immunohistochemistry Standardization in your Laboratory: Renewable ...Candy Smellie
What is the impact of assay failure in your laboratory and how do you monitor for it?
To develop genetically defined IHC Reference Standards with consistent protein expression levels for analytic validation and quantitative assessment of immunohistochemistry assays.
Platform Technologies to Accelerate Novel Vaccine Development and ManufacturingMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3jmLYHu
State-of-the-art vaccine technologies are transforming vaccine development, and solutions for fast and reliable production are needed.
The vaccine industry has undergone a revolution in technology resulting in a variety of novel therapeutic platforms that accelerate development and significantly reduce the duration for process optimization and scale-up. However, challenges in maintaining efficacy and improving process robustness remain. In this presentation, we present a comparison of these novel technologies, discuss key considerations for manufacturing and share selected case studies for platforms such as virus-like-particles, viral vectors, plasmid DNA, and mRNA platform.
In this webinar, you will learn:
• Benefits of platform technologies in vaccine development
• Key considerations when deciding between platforms
• Vaccine pipeline analysis and selected case studies
Presented by:
David Loong, Ph.D, Senior Consultant, Novel Modalities Asia Pacific, Bioprocessing Strategy
Josephine Cheng, Senior Consultant, Core Modalities Asia Pacific, Bioprocessing Strategy
Creative Biolabs is a leading service provider that focuses on antibody engineering for research, diagnostic and therapeutic use. Our service portfolio includes antibody affinity maturation, antibody stability improvement, chimeric antigen receptor (CAR) construction, scFv/Fab construction and other antibody specialization and modification services.
Antibody screening is more helpful in identifying the
highly productive cells and is more significant in the
form of laboratory techniques. Complete solution on screening
of antibodies can be effectively offered only
by such kinds of reputed medical institutions.
For more details please visit
http://www.axiomxinc.com/
The Future of Allergy and Clinical Immunology Prof. G. Walter Canonica - Con...Juan Carlos Ivancevich
Prof.G.Walter Canonica
Allergy and Respiratory Diseases Clinic
DIMI-‐University of Genoa
Italy
Presidente Congreso SLaai 2015: Dr. Alfonso Cepeda Sarabia
PEGS Europe Protein & Antibody Engineering Summit 2014 AgendaNicole Proulx
PEGS Europe is the largest European event covering all aspects of protein and antibody engineering. With two consecutive years of 40% growth in attendance, and another year of expanded program coverage, this year’s event will feature:
•500 attendees
•150 technical presentations
•70+ scientific posters
•40+ sponsors & exhibitors
•Dedicated networking opportunities
•Exclusive exhibit & poster hours
•Interactive roundtable, breakout & panel discussions
Providing a focal point to push industry collaboration through updates on clinical advancements and investment opportunities, SMi presents the 20th annual Superbugs & Superdrugs conference which will return to Central London on 19th and 20th March 2018.
The threat of AMR is regularly making front page news but what is the industry actually doing? Are drug manufacturers any closer to finding a solution and how is the government helping? These will be just some of the questions answered through powerful keynote addresses delivered by an expert panel of scientific leaders, drug discovery specialists and government bodies such as MHRA and DNDi.
Immunogenicity and Bioassay Summit, Baltimore, MD November 17-19, 2015David Cunningham
Thinking about attending the Immunogenicity and Bioassay Summit, but have questions? I would be more than happy to walk you through the program agenda, pricing options and answer any questions you may have. In the meantime, don’t forget about the savings deadline coming up Friday, October 16th!
Call David at 781-972-5472 if you would like to join us!
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
1. www.immuno.co.uk
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
ACADEMIC & GROUP DISCOUNTS AVAILABLE
A: Approaches to standardising assays for measuring drug levels
and anti drug antibodies to biotherapeutics in clinical practice
Workshop Leaders:
Hishani Kirby, Founder and Director, Hishani Kirby Associates Ltd
Daniel Sikkema, Executive Director, Head of Immunogenicity
and Clinical Immunology, GlaxoSmithKline
08.30 – 12.30
B: Unwanted immunogenicity from
bench to bedside
Workshop Leaders:
Arno Kromminga, CEO/CSO, IPM Biotech
Sofie Pattijn, Chief Technology Officer, ImmunXperts
13.30 – 17.30
PLUS TWO INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOPS
Wednesday 15th June 2016, Holiday Inn Kensington Forum, London, UK
REGISTER BY 31ST MARCH AND RECEIVE A £400 DISCOUNT
REGISTER BY 29TH APRIL AND RECEIVE A £200 DISCOUNT
@SMIPHARM
#immunosmi
SMi Present the 3rd Annual Conference on…
Immunogenicity
Holiday Inn Kensington Forum, London, UK
13 - 14
JUNE
2016
Accelerating commercialisation of your
next gen biotherapeutics – adopt advanced
immunogenicity assessments for successful
regulatory approval
Key Sessions:
• MHRA: Towards harmonisation of immunogenicity assays
• Integration of immunogenicity risk data to forecast clinical
outcomes
• A harmonised approach to interpretation and reporting of
clinical immunogenicity data
• Development and validation of cell based antibody
neutralisation assays
Sponsored by
Chairs for 2016:
Annie De Groot,
CEO and CSO,
EpiVax, Inc.
Adnan Khan,
Senior Scientist Immunology/Pharmacology,
UCB
Featured Speakers:
• Meenu Wadhwa, Section Leader, Cytokines and Growth
Factors, NIBSC, MHRA
• Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences
• Daniel Sikkema, Executive Director, Head of Immunogenicity
and Clinical Immunology, GlaxoSmithKline
• Jochem Gokemeijer, Associate Director, Bristol-Myers Squibb
• Tim Hickling, Immunogenicity Sciences Discipline Lead, Pfizer
2. Immunogenicity
Day One | Monday 13th June 2016
Register online at: www.immuno.co.uk • Alternatively fax your
Sponsored by
08.30 Registration & Coffee
09.00 Chairman’s Opening Remarks
Annie De Groot, CEO and CSO, EpiVax, Inc.
OPENING ADDRESS
09.10 Improving the efficacy and safety profile of
biotherapeutics by addressing product immunogenicity
with tolerogenic nanoparticles
• The development of anti-drug antibodies (ADAs) is
a common cause for treatment failure and adverse
events associated with biologic therapies.
• Addressing product immunogenicity has the potential
to improve efficacy and safety profile of novel biologics;
reduce catastrophic late stage clinical failure due
to ADAs; provide life cycle management for existing
products; and differentiate products from biosimilars.
• Selecta Biosciences is a clinical stage company that
has developed a novel platform of Synthetic Vaccine
Particles (SVP) to induce durable antigen-specific
immune tolerance for the prevention of ADAs
Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences
09.50 Redefining the well-defined: unwanted immune responses
• What is an unwanted immune response?
• What can we define as tolerance?
• Therapeutic innervation and innovation
Adnan Khan, Senior Scientist Immunology/Pharmacology, UCB
10.30 Morning Coffee
11.00 A harmonised approach to interpretation and reporting of
clinical immunogenicity data
• How can we harmonise data?
• Should we be able to compare trial results that use
different ranking methods
• The benefits a harmonised approach can bring to the
reporting of clinical immunogenicity data
Daniel Sikkema, Executive Director, Head of
Immunogenicity and Clinical Immunology,
GlaxoSmithKline
KEYNOTE ADDRESS
11.40 Towards harmonisation of immunogenicity assays
• Wide variation in ADA incidence and titres often
reported for a therapeutic
• Should we produce reference panels or standardise
methods to harmonise data?
• Availability of a WHO reference panel for erythropoietin
antibody assays
Meenu Wadhwa, Section Leader, Cytokines and Growth
Factors, NIBSC, MHRA
12.20 Networking Lunch
13.20 Immunogenicity risk assessment tools for biologics
• Immunogenicity risk assessment tools to inform biologics
development programs
• Utilisation of immunogenicity tools to guide critical
quality attributes (CQA) for product attributes
• Challenges in clinical validation of immunogenicity risk
assessment
Jochem Gokemeijer, Associate Director, Bristol-Myers Squibb
14.00 Integrating best-in-class in vitro and ex vivo assays to
manage immunogenicity risk in biologics
• Learn how data from cell-based assays, physical
MHC-peptide binding assays and mass spectrometry
antigen presentation assays can be integrated to
characterize immune responses against, or caused by,
biotherapeutic drugs
• Mitigate the risk of first infusion reactions using whole-
blood cytokine release assay
• Improve decision-making in lead selection, lead
characterisation and re-engineering options
Jeremy Fry, Director of Sales, ProImmune Ltd.
14.40 Afternoon Tea
15.10 Nanobodies, a promising new class of
biopharmaceuticals. What about their immunogenicity?
• Nanobodies originate from camelids, but does their
humanisation make sense?
• Different methods for anti-drug antibodies (ADA)
assessment towards nanobodies
• In vitro immunogenicity risk assessment of nanobodies
Chloé Ackaert, Postdoctoral Researcher,
Free University of Brussels
15.50 Understanding the role of aggregation in the
immunogenicity of biotherapeutic proteins
• Comparison of the immunological responses to
immunisation with recombinant biologics in monomeric
and aggregated forms in a mouse model
• The results were generally indicative of skewing towards
a Th1-type response
• Can HCPs also play a role in modulating the immune
response?
Jeremy Derrick, Professor, University of Manchester
16.30 Chairman’s Closing Remarks and Close of Day One
Annie De Groot, CEO and CSO, EpiVax, Inc.
Abzena offers a suite of complementary services
and technologies. Its range of technologies
include immunogenicity assessment, antibody drug
conjugation, protein engineering, PEGylation, cell
line development, GMP manufacturing and a range
of bespoke assays to enables the development
of better biopharmaceuticals which will have a
greater chance of reaching the market.
www.abzena.com
Sponsorship and Exhibition Opportunities
SMi offer sponsorship, exhibition, advertising
and branding packages, uniquely tailored
to complement your company’s marketing
strategy. Prime networking opportunities exist to
entertain, enhance and expand your client base
within the context of an independent discussion
specific to your industry.
Should you wish to join the increasing number
of companies benefiting from sponsoring our
conferences please call:
Alia Malick on +44 (0) 20 7827 6168 or
email: amalick@smi-online.co.uk
EXPLORING IMMUNOGENIC ASSESSMENT TECHNIQUES
NEXT GENERATION BIOLOGICS
3. Immunogenicity
Day Two | Tuesday 14th June 2016
08.30 Registration and Coffee
09.00 Chairman’s Opening Remarks
Adnan Khan, Senior Scientist Immunology/Pharmacology, UCB
OPENING ADDRESS / KEYNOTE ADDRESS
09.10 Development and validation of cell based antibody
neutralisation assays
• Examples of validation of cell based neutralisation
assays
• Their application to release / stability testing of vaccines
• Consideration of the assay life cycle
Sue Charlton, Scientific Lead, Vaccine Research Group,
Public Health England
09.50 Integration of immunogenicity risk data to forecast clinical
outcomes
• Immune responses to biologics as a normal response to
drug exposure
• Identifying key risk factors for immunogenicity
• Working with protein engineers to reduce
immunogenicity of biotherapeutics
• Utilising non-clinical assays for immunogenicity
assessment
Tim Hickling, Immunogenicity Sciences Discipline Lead, Pfizer
10.30 Morning Coffee
11.00 Influence of aggregates on in vitro T cell responses
• Immunogenicity of therapeutic protein products can
elicit unwanted ADA
• Protein aggregation can result in enhanced
immunogenicity
• In vitro methods that measure the impact of these
aggregates on enhanced immunogenicity will be useful
tools in screening processes to avoid or reduce problems
associated with ADA
Mark Fogg, Immunology Group Leader, Abzena
11.40 T-cell amplification assays for immunogenicity prediction:
T-cell repertoire and epitopes
• Why are T cell assays performed to predict
immunogenicity?
• What kind of data do they produce?
• Do they have been already confronted to clinical
observations?
• Are they really useful as compared to other predictive
approaches?
Machteld Tiemessen, Senior Scientist, Janssen
12.20 Networking Lunch
13.20 Correlation of T-cell responses induced by therapeutic
cancer vaccines with clinical responses
• In premalignant disease caused by high risk HPV,
therapeutic vaccination-induced T-cell responses
correlate with clinical responses
• In late stage HPV-induced cancer myeloid cell
depletion by standard chemotherapy fosters robust
vaccine-induced T cell responses
• Therapeutic vaccines works as monotherapy in pre-
malignant disease, but treatment of late stage cancer
requires combination of vaccination with immuno-
modulation
Kees Melief, Chief Scientific Officer, ISA Pharmaceuticals
Ronald Loggers, Chief Executive Officer, ISA Pharmaceuticals
14.00 A computational pipeline for personalised cancer vaccine
development
• Checkpoint inhibitors are changing cure rates for
cancer and generating excitement in the cancer field
• While cure rates are improving, personalised cancer
vaccines may improve cure rates even further
• Personalised cancer vaccines are feasible using
available computational tools
• Participants will learn how personalised cancer vaccines
will move the needle on cancer cures of the future
Annie De Groot, CEO, EpiVax
14.40 Afternoon Tea
15.10 Immunogenicity of biosimilar monoclonal antibodies
• Unexpected immunogenicity linked to biosimilar
monoclonal antibodies
• The challenge of assessing similarity between originator
and biosimilar mAb
• Developing a characteriation strategy for proving
comparability with biosimilars
Andreas Herrmann, CEO, Baliopharm AG
15.50 Protein aggregates: Why do we need to study them?
Quantification and characterisation of sub-visible particles
in protein therapeutics
• Biopharmaceutical and problems never seen with non-
protein substances
• Protein aggregates structure and function
• Strategy in analysis and characterization of protein
aggregates
Mantas Malisauskas, Manager R&D, Baxalta
16.30 Chairman’s Closing Remarks and Close of Day Two
Adnan Khan, Senior Scientist Immunology/Pharmacology, UCB
registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
Want to know how you can get involved? Interested in promoting your services to this market?
Contact Anna Serazetdinova, SMi Marketing on +44 (0) 207 827 6180 or email: aserazetdinova@smi-online.co.uk
Supported by
A CLOSER LOOK AT ADAPTIVE T CELLS
INNOVATIONS IN IMMUNOGENICITY
Official Publications
4. A: Approaches to standardising assays
for measuring drug levels and anti drug
antibodies to biotherapeutics in
clinical practice
Workshop Leaders:
Hishani Kirby, Founder and Director,
Hishani Kirby Associates Ltd
Daniel Sikkema, Executive Director, Head of Immunogenicity
and Clinical Immunology, GlaxoSmithKline
HALF-DAY POST-CONFERENCE WORKSHOP
Wednesday 15th June 2016
08.30 – 12.30
Holiday Inn Kensington Forum, London, UK
Overview of Workshop:
The assay requirements for rapid decision making with licenced
biotherapeutics in clinical practice can be very different from the
bestpracticeappliedduringregulatedstudies.Thegrowingtrend
for therapeutic drug monitoring (TDM) with biotherapeutics has
highlighted the need for harmonisation of assays and associated
data throughout the lifecycle of a given drug.
In this workshop, an overview of historical approaches to
validating methods to quantify biopharmaceuticals and to
detect, monitor, and characterise anti-drug antibodies will
be presented. The current best practices, terminology, and
future insights for standardisation of methods and associated
technological developments will be discussed.
You will be able to learn about the latest trends and
developments for quantifying biotherapeutics and monitoring
anti-drug antibodies will be presented in the context of assay
harmonisation, associated challenges and possible solutions.
Programme:
08.30 Registration
09.00 Workshop Leaders Introduction
09.10 Overview of historical approaches for drug and ADA
measurement: Fit for purpose?
• Which format?
• What are the parameters?
• Constraints and challenges
10.30 Morning Coffee
11.00 Looking beyond – technological developments
• Future standardisation of methods
• Advanced quantification techniques for
biotherapeutics and
application on immunogenicity
• Associated challenges and solutions
12.00 Q&A
12.30 End of Workshop
About the Workshop Leader:
Hishani Kirby, PhD, Founder and Director,
Hishani Kirby Associates Ltd
With over 25years in the biopharmaceutical industry,
Hishani has gained wide experience in the development of
biopharmaceutical products. This has been mainly with Mab and
Mab-basedfragments,whereshehasutilisedherextensiveprotein
analytical and bioanalytical expertise, in the characterisation and
measurement of complex biotherapeutics. Hishani first estalished
her career at Celltech in Mab therapeutics and then joined UCB,
where she was responsible for providing expert guidance on
bioanalytical strategy in PK, PD and immunogenicity in support of
the company’s portfolio from discovery through to post licencing
phases of development, as well as leading the team responsible
for execution of analytical and bioanalytical services.
More recently, Hishani has formed her own consulting
company providing expertise in scientific aspects of bioanalysis,
immunogenicity risk assessment and testing strategies, and in
regulatory considerations in biopharmaceutical development.
Her strengths are in designing and implementing practical/
innovative analytical solutions to enable rapid decision making
through development to post license life cycle management.
DanielSikkema,ExecutiveDirector,HeadofImmunogenicityand
Clinical Immunology, GlaxoSmithKline
DanjoinedGlaxoSmithKline(GSK)asExecutiveDirectorandHead
oftheClinicalImmunologygroupinBioPharmR&DinAugust2010.
Priortothis,hehadheldvariouspositionsofincreasingresponsibility
at Bristol-Myers Squibb, Wyeth Vaccines, Merck Vaccines and
Biologics, and Sanofi Pasteur. Dan has contributed to the clinical
immunology and microbiology assessments leading to licensure
of Prev(e)nar, Meningitec, Gardasil, Rotavax, ProQuad, and
Zostavax, and has worked extensively with the WHO, US Centers
for Disease Control, National Institute for Biological Standards
and Controls, US FDA, and EMA. Now at GSK he is heading
the Immunogenicity and Clinical Immunology group assessing
immunogenicity of administered biotherapeutics and the
quantitation of target-engaged biomarkers in the clinical setting,
aswellasleadingtheInnovativeMedicinesInitiative(www.abirisk.
eu) to further understand the underlying mechanisms and basic
biology around induction of immunogenicity to biotherapeutics
and their clinical relevance. July 1, 2015, he assumed the Chair
Elect position for Division V at American Society for Microbiology.
5. B: Unwanted immunogenicity from
bench to bedside
Workshop Leaders:
Arno Kromminga, CEO/CSO, IPM Biotech
Sofie Pattijn, Chief Technology Officer, ImmunXperts
HALF-DAY POST-CONFERENCE WORKSHOP
Wednesday 15th June 2016
13.30 – 17.30
Holiday Inn Kensington Forum, London, UK
Overview of Workshop:
This workshop will give an insight on the rapid growing
field of unwanted immunogenicity and the science
behind it. The immunology of an unwanted immune
response will be addressed and discussed. Also,
an overview of the tools for early immunogenicity
assessment will be given. Finally, the emerging trends
and clinical impact of neutralising anti-drug antibodies
will be discussed followed by a summary of the lessons
learned and future challenges.
Programme:
13.30 Registration
14.00 The immunology of immunogenicity
14.45 Tools for early non-clinical immunogenicity
assessment
15.30 Afternoon Tea
16.00 Neutralising anti-drug antibodies:
Emerging trends and clinical impact
16.45 Lessons learned and future challenges
17.20 Closing remarks
17.30 Close of workshop
About the Workshop Leaders:
Dr Arno Kromminga is currently CSO of GLP-certified
IPM Biotech. In addition, he is a faculty member at
the Institute of Immunology at the University of Kiel. He
studied Biochemistry and Immunology and has 20+
years experience in assay development, is author of
multiple publications in peer-reviewed journals and
books and is a co-founder and board member of
the European Immunogenicity Platform (EIP). He and
his team have developed and validated numerous
immunological binding and cellular functional assays
for immunogenicity testing and PK/PD analysis for pre-
clinical and clinical studies. His major interest besides
the validation of assays, is the interpretation of results to
obtain clinically meaningful data
Sofie Pattijn (CTO, ImmunXperts) has over 20 years of
experience in the field of immunogenicity assessment
(vaccines and biotherapeutics). She has extensive
hands-on lab experience and has managed and
coached several In Vitro teams over the last decade.
From 2008 till 2013 she was Head of the In Vitro
Immunogenicity group at AlgoNomics (Ghent, Belgium)
and Lonza Applied Protein Services (Cambridge, UK).
Prior to that, she worked at Innogenetics, Belgium for
over 15 years.
6. Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Payment: If payment is not made at the time of booking, then an invoice will be issued and must
be paid immediately and prior to the start of the event. If payment has not been received then
credit card details will be requested and payment taken before entry to the event. Bookings within
7 days of event require payment on booking. Access to the Document Portal will not be given until
payment has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send
a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge,
providing that cancellation is made in writing and received at least 28 days prior to the start of the
event. Regretfully cancellation after this time cannot be accepted. We will however provide the
conferencesdocumentationviatheDocumentPortaltoanydelegatewhohaspaidbutisunable
to attend for any reason. Due to the interactive nature of the Briefings we are not normally able
to provide documentation in these circumstances. We cannot accept cancellations of orders
placed for Documentation or the Document Portal as these are reproduced specifically to order.
If we have to cancel the event for any reason, then we will make a full refund immediately, but
disclaim any further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection
Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about
other products and services. Unless you tick here □ we may also share your data with third parties
offeringcomplementaryproductsorservices.Ifyouhaveanyqueriesorwanttoupdateanyofthe
data that we hold then please contact our Database Manager databasemanager@smi-online.
co.uk or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your
address on the attached letter.
Payment must be made to SMi Group Ltd, and received before the event, by one of the
following methods quoting reference P-176 and the delegate’s name. Bookings made within
7 days of the event require payment on booking, methods of payment:
□ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
□ Cheque We can only accept Sterling cheques drawn on a UK bank.
□ Credit Card □ Visa □ MasterCard □ American Express
All credit card payments will be subject to standard credit card charges.
Card No: □□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
Card Billing Address (If different from above):
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged
on Document portal and literature distribution for all UK customers and for those EU
Customers not supplying a registration number for their own country here.
______________________________________________________________________________________
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email events@smi-online.co.uk
□ Book by 31st March to receive £400 off the conference price
□ Book by 29th April to receive £200 off the conference price
EARLY BIRD
DISCOUNT
I would like to attend: (Please tick as appropriate) Fee Total
□ Conference & 2 Workshops £2697.00 + VAT £3236.40
□ Conference & 1 Workshop A □ B □ £2098.00 + VAT £2517.60
□ Conference only £1499.00 + VAT £1798.80
□ 2 Workshops £1198.00 + VAT £1437.60
□ 1 Workshop only £599.00 + VAT £718.80
Workshop A □ Workshop B □
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
literature to all conference attendees £999.00 + VAT £1198.80
The conference fee includes refreshments, lunch, conference papers, and access to
the Document Portal. Presentations that are available for download will be subject to
distribution rights by speakers. Please note that some presentations may not be available
for download. Access information for the document portal will be sent to the e-mail
address provided during registration. Details are sent within 24 hours post conference.
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: events@smi-online.co.uk or fax +44 (0) 870 9090 712
I cannot attend but would like to purchase access to the following
Document Portal/paper copy documentation Price Total
□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations – paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
Unique Reference Number
Our Reference LVP-176
DELEGATE DETAILS
Terms and Conditions of Booking
PAYMENT
VAT
CONFERENCE PRICES
DOCUMENTATION
VENUE Holiday Inn Kensington Forum, 97 Cromwell Rd, London SW7 4DN, UK
IMMUNOGENICITY
Conference: Monday 13th & Tuesday 14th June 2016, Holiday Inn Kensington Forum, London, UK Workshops: Wednesday 15th June 2016, London, UK
4 WAYS TO REGISTER
www.immuno.co.uk
FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor
South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK